Daiichi Sankyo Co., Ltd.

Industry

  • Biotechnology
  • Pharmaceuticals
    • Vaccines
    • Generic Drugs

Other Names/Subsidiaries

  • Ambit Biosciences
  • American Regent
  • Asubio Pharmaceuticals
  • Daiichi Sankyo Espha
  • Daiichi Sankyo Europe
  • Daiichi Sankyo Healthcare
  • Daiichi Sankyo India Pharma
  • Daiichi Sankyo RD Novare
  • Daiichi Sankyo Vaccine
  • Daiichi Sankyo Vietnam Company
  • Im
  • Kitasato
  • Kitasato Daiichi Sankyo K.K.
  • Kitasato Daiichi Sankyo Vaccine
  • Luitpold Pharmaceuticals (American Regent
  • PharmaForce)
  • Plexxikon
  • Ranbaxy Laboratories
  • ROXRO Pharma
  • Sankyo Pharma
  • Shanghai Xinshengyuan Pharmaceutical Group
  • Suntory Pharmaceutical
  • U3 Pharma
  • Zenotech Laboratories
See more in Biomedtracker

Latest on Daiichi Sankyo Co., Ltd.

Scrip

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

Bliss Biopharmaceutical (Hangzhou) (BlissBio), a Chinese developer of antibody-drug conjugates (ADCs), will rely on itself to advance BB-1701, a HER2-targeting ADC carrying the microtubule inhibitor e

Scrip

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

BioNTech’s acquisition of fellow German mRNA company CureVac underscored a trend in biotech: many companies form around new technologies, but not all succeed. A Very German Transaction BioNTech’s acq

Scrip

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo

Scrip

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan), used in combination with Roche’s HER2-targeting Perjeta (pertuzumab), has potential to change